Q3 Earnings Estimate for Stereotaxis Issued By Roth Capital

Stereotaxis Inc. (NYSEAMERICAN:STXS) – Stock analysts at Roth Capital issued their Q3 2025 earnings estimates for Stereotaxis in a research report issued on Wednesday, November 5th. Roth Capital analyst K. Bauser forecasts that the company will post earnings of ($0.06) per share for the quarter. Roth Capital has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Stereotaxis’ current full-year earnings is ($0.26) per share. Roth Capital also issued estimates for Stereotaxis’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.23) EPS.

Separately, UBS Group set a $4.00 target price on Stereotaxis in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.00.

Stereotaxis Stock Performance

NYSEAMERICAN STXS opened at $2.68 on Friday. The firm has a market capitalization of $244.07 million, a P/E ratio of -9.24 and a beta of 1.65. The stock has a 50-day simple moving average of $2.96 and a two-hundred day simple moving average of $2.51. Stereotaxis has a fifty-two week low of $1.54 and a fifty-two week high of $3.59.

Institutional Investors Weigh In On Stereotaxis

Institutional investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in shares of Stereotaxis in the 1st quarter valued at about $37,000. Nuveen LLC purchased a new position in Stereotaxis during the first quarter worth approximately $130,000. Essex Investment Management Co. LLC boosted its position in Stereotaxis by 28.3% during the first quarter. Essex Investment Management Co. LLC now owns 1,556,094 shares of the company’s stock worth $2,739,000 after purchasing an additional 343,130 shares in the last quarter. Deutsche Bank AG acquired a new stake in Stereotaxis in the first quarter valued at approximately $82,000. Finally, Independent Advisor Alliance increased its position in shares of Stereotaxis by 3.2% in the first quarter. Independent Advisor Alliance now owns 191,695 shares of the company’s stock valued at $337,000 after buying an additional 5,900 shares in the last quarter. 45.35% of the stock is currently owned by institutional investors and hedge funds.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.